本报讯 8月26日晚，保龄宝生物股份有限公司（以下简称"保龄宝"）披露2025年半年度报告，公司上半 年业绩表现亮眼，营收、净利润均实现双位数增长，核心产品减糖甜味剂业务增速尤为突出，同时在新 品研发与产能布局上持续发力。 益生元业务同样稳健，实现收入1.89亿元，同比增长20.23%，毛利率提升0.62个百分点至25.03%，低聚 异麦芽糖等主力产品全球市占率优势稳固。膳食纤维业务受市场环境影响收入略有下滑，但整体产品结 构向高附加值方向优化。 （文章来源：证券日报） 此外，公司推出2025年限制性股票激励计划，绑定核心团队利益，考核目标为2025年至2027年累计归母 净利润不低于6.47亿元，为长期发展注入动力。 研发与产能布局方面，公司上半年新增3项发明专利授权，参与修订5项国家标准，"D-阿洛酮糖产业化 关键技术研发及应用"项目获山东省科技奖项。产能端，年产2万吨阿洛酮糖（二期）项目已启动建设， 母乳低聚糖（HMOs）、DHA藻油等新项目预计下半年投产，未来将进一步丰富产品矩阵。 报告显示，2025年上半年，保龄宝实现营业收入13.99亿元，同比增长18.02%；归属于上市公司股东的 净利润9267 ...

8月26日晚，代糖行业龙头企业保龄宝（002286）发布2025年半年度报告，报告期内实现营业收入13.99 亿元，同比增长18.02%；净利润9267.2万元，同比增长33.66%。 值得关注的是，今年1月16日，欧盟委员会公布了关于本次赤藓糖醇反倾销调查终裁公告，对国内赤藓 糖醇生产企业征收34.4%-233.3%不等的反倾销税。上述反倾销措施于欧盟终裁公告发布次日(即2025年1 月17日)起生效，实施期限为5年。其中保龄宝相关产品被征收34.4%的反倾销税，为本次反倾销加征税 率最低的企业。 保龄宝表示，公司抓住反倾销税率最低带来的市场机遇，赤藓糖醇产品在欧洲地区实现量价齐升，良好 的国际影响力和品牌力也带动了国内销售。 项目建设进展方面，保龄宝于2024年利用部分富裕产线进行改造，建立了DHA藻油生产线，初步计划 年产2000吨DHA藻油毛油。同年，该公司启动乳果糖项目的生产及上市许可注册工作。此外，保龄宝 还启动新建"年产2,500吨HMOs(母乳低聚糖)建设项目"。上述项目预计2025年下半年投产。 2025年3月，保龄宝了启动年产2万吨阿洛酮糖(二期)扩产项目，目前已完成备案正在建设中。预计2 ...

2025年半年度，公司产品综合毛利率进一步提升至13.17%，较去年同期提高1.36%。三大核心产品（益 生元、膳食纤维、减糖甜味剂）实现收入6.64亿元，同比增长32.15%，毛利率较去年同期提升1.93%至 17.94%。 8月26日，保龄宝发布2025年半年报。当中披露，2025年上半年，公司实现营业总收入 13.99亿元，同比 增长18.02%；实现归属净利润9267.20万元，同比增长33.66%。公司业绩增长主要原因为公司核心产品 减糖甜味剂、益生元等销量同比大幅增长，收入占比持续提升以及降本增效导致毛利率改善所致。 （企业公告） ...

Core Insights - The strategic cooperation for "产研融合加速 赋能肠道健康" was launched in Beijing, involving the brand "轻又清," BioNeutra, 惠买集团, and Qingdao Agricultural University, aiming to enhance the international development of the prebiotic industry in China [1][14] - The event highlighted the growing concern over gut health issues, which have become significant due to dietary imbalances, and emphasized the importance of prebiotics like inulin for gut function recovery [3][9] - The prebiotic market is experiencing rapid growth, with the Chinese prebiotic market currently valued at 150 billion, growing at an annual rate of 10% [13] Company and Industry Developments - "轻又清" has received strategic investment from BioNeutra and 惠买集团, with a valuation in the tens of millions, indicating strong market confidence [1] - 惠买集团 plans to open 10,000 health supermarkets nationwide within two years, aiming to enhance its offline customer acquisition channels [9] - The collaboration between "轻又清," BioNeutra, 惠买集团, and Qingdao Agricultural University is expected to inject strong momentum into the prebiotic industry, enhancing product innovation and market competitiveness [20] - Investment institutions like 深创投 and 中信建投 are optimistic about the prebiotic sector, viewing it as a necessary investment option for the future [11][13]

Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [1][16] Core Views - The company has shown continuous revenue and profit growth due to product structure adjustments and the ramp-up of new production capacity. The approval of allulose in China is expected to drive market demand [2][4][16] - Allulose has functional advantages such as low calories, antioxidant properties, and neuroprotection, which will effectively fill the gap in China's functional sweetener market [14][16] - The company currently has a production capacity of 15,000 tons of allulose crystals and plans to build nearly 20,000 tons of allulose capacity in Thailand to meet domestic and international demand [3][14][16] Financial Performance - For the first half of 2025, the company achieved total revenue of 650 million yuan, a year-on-year increase of 22.29%, and a net profit attributable to shareholders of 171 million yuan, a year-on-year increase of 42.68% [2][4] - The second quarter of 2025 saw revenue of 337 million yuan, a year-on-year increase of 20.79%, and a net profit of 90 million yuan, a year-on-year increase of 36.36% [2][4] - The company’s net profit forecasts for 2025-2027 are 346 million yuan, 431 million yuan, and 503 million yuan, representing year-on-year growth rates of 40.8%, 24.7%, and 16.6% respectively [3][16] Market Outlook - The global allulose market has grown from 33 million USD in 2019 to 173 million USD in 2023, with a compound annual growth rate of 33.26%. It is expected to reach 545 million USD by 2030 [11] - The approval of allulose as a new food ingredient in China is anticipated to significantly boost domestic demand [8][10][16] - Allulose is positioned as a safer and more effective sugar substitute compared to artificial sweeteners, which have been linked to health risks [14][16]

Group 1: Wind Power Gearbox Industry - The report highlights the scarcity of wind power gearboxes, with a focus on the expected performance and valuation elasticity due to increased production capacity and orders [2][24][25] - The company has completed its precision wind power gearbox production project, with a significant increase in sales expected in 2025, leading to a projected gross margin recovery to 16.6% by 2025, an increase of 10 percentage points from 2024 [2][25] - A strategic cooperation agreement with Goldwind Technology was signed in October 2024, establishing a foundation for future orders, with the gearbox (speed increaser) accounting for 23% of the value, which is nine times that of the reducer, indicating substantial growth potential [2][25][26] Group 2: Functional Sugar Industry - The report indicates that the company is the largest producer of oligosaccharides globally, with a focus on functional sugars, which are expected to see rapid growth in demand [27][30] - The company has optimized its operational strategies and management efficiency, leading to a return to growth in 2024, with significant contributions from prebiotics and sugar substitutes [27][28] - Future production expansions include a 20,000-ton alulose sugar project starting in March 2025 and the introduction of new products using synthetic biology technology, which are expected to enhance profitability [31][32] Group 3: Construction and Chemical Engineering Industry - The report emphasizes the rising investment opportunities in infrastructure in the central and western regions of China, particularly in Xinjiang and Tibet, driven by the Belt and Road Initiative [3][43][45] - The chemical engineering sector is expected to benefit from the acceleration of coal chemical projects, with a total investment exceeding 1.4 trillion yuan, indicating strong order support for chemical engineering companies [3][46] - The report recommends companies such as Sany Road and Bridge, China Energy Construction, and China Electric Power Construction as key players in the infrastructure and chemical engineering sectors [3][44][46]

Company Overview - Baolingbao is a leading company in the functional sugar sector, focusing on the research, production, and sales of prebiotics, sugar-reducing sweeteners, and dietary fibers, with an annual comprehensive production capacity exceeding 500,000 tons and over 2,000 active customers [2][3] - The company has recently appointed Mr. Wang Qiang as the general manager, who has extensive management experience in food raw material companies [2] Performance and Growth Strategy - In 2024, Baolingbao is expected to achieve a significant profit increase through proactive adjustments in product structure and marketing strategies, while also adjusting revenue [2] - The company has set ambitious performance targets for 2025-2027, with net profit goals of at least 170 million yuan in 2025, a cumulative total of at least 382 million yuan for 2025-2026, and at least 647 million yuan for 2025-2027 [2] Industry Trends - The functional sugar industry is experiencing rapid growth driven by demographic changes, consumer preferences, and policy guidance, with a shift from traditional sweeteners to healthier alternatives [3] - The demand for sugar substitutes and functional sugars is on the rise, indicating a favorable market environment for Baolingbao's products [3] Product Focus - Baolingbao is the largest producer of isomaltooligosaccharides globally, with prebiotics being the primary source of gross profit in 2024 [4] - The company is also a pioneer in the industrial production of erythritol and is expanding its market share internationally, with erythritol sales revenue increasing by 52.58% year-on-year in 2024 [4] Future Prospects - The company plans to launch several new products utilizing synthetic biology technology in the next 1-2 years, including new capacities for erythritol and a 20,000-ton expansion project for allulose starting in March 2025 [5] - Baolingbao's revenue projections for 2025-2027 are 2.574 billion yuan, 2.794 billion yuan, and 3.069 billion yuan, respectively, with net profits of 170 million yuan, 221 million yuan, and 274 million yuan [5]

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 13.5 CNY, based on a current price of 11.08 CNY [7]. Core Viewpoints - The company is positioned as a leader in the functional sugar sector, with a focus on optimizing management efficiency and strategies to return to a growth trajectory in 2024 [1][16]. - The company has set ambitious profit targets for 2025-2027, with a minimum net profit of 1.7 billion CNY in 2025 and cumulative targets of 3.82 billion CNY and 6.47 billion CNY for 2025-2026 and 2025-2027, respectively [1][25]. Summary by Sections Company Overview - The company specializes in the research, production, and sales of functional ingredients such as prebiotics, sugar-reducing sweeteners, and dietary fibers, with an annual capacity exceeding 500,000 tons and over 2,000 active customers [1][16]. Industry Transformation - The functional sugar industry is experiencing rapid growth driven by demographic changes, consumer preferences, and policy guidance, leading to a shift from traditional sweeteners to healthier alternatives [2][54]. Product Focus - The company is the largest producer of isomalto-oligosaccharides globally and has seen a 52.58% increase in sales revenue from erythritol in 2024, capitalizing on opportunities in international markets [3][56]. Future Prospects - The company plans to launch new products utilizing synthetic biology technology and expand production capacity for erythritol and allulose, with significant projects set to commence in 2025 [4][56]. Financial Forecast & Investment Recommendations - Revenue projections for 2025-2027 are 2.57 billion CNY, 2.79 billion CNY, and 3.07 billion CNY, with corresponding net profits of 170 million CNY, 221 million CNY, and 274 million CNY [5][6]. The report highlights the company's strong growth potential and recommends a target price based on a 30x PE ratio for 2025 [5].

Company and Industry Summary Company Overview - The company primarily exports products and is positioned in the customized mid-to-high-end market, which makes it less affected by domestic price competition [2][8] - A 20% tariff is borne by customers, thus having no direct impact on the company's operating performance [2][4] Capacity Expansion Plans - The company plans to add 20,000 tons of capacity in 2025, with completion expected by the end of the year, and partial production starting in 2026 [2][5] - A project in Thailand with a capacity of 49,000 tons is expected to be completed by the end of 2026 and to start production in 2027 [2][5][28] Market Dynamics - The acceptance of functional sugars in the European and American markets is high, particularly for mid-to-high-end products, although certification is strict [2][9] - The Chinese market focuses on cost-effectiveness but is gradually transitioning to high-end products, with a potential lag of 3-5 years compared to Europe and the U.S. [2][9][30] Product Insights - Allulose, a health sweetener, is in the early stages of global market acceptance and has not yet been approved in China, but domestic manufacturers are already incorporating it into their products [2][10] - The current average selling price of allulose is around 25,000 yuan, with a cost reduction of about 10% [2][13] - The market demand for allulose is expected to be no less than that for erythritol, indicating significant potential [2][13] Growth Projections - The resistant dextrin market is growing steadily, with the company achieving over 50% annual growth, limited by capacity [2][15] - The expected production of resistant dextrin in 2024 is projected to be 10,000 to 20,000 tons, doubling from 2023 [2][15] Financial Performance - The company's overall performance in Q2 2025 is expected to be better than Q1, despite a temporary export halt due to tariff policies [3][18] - The gross margin for allulose improved from 24% to 34% in Q1, while resistant dextrin margins range from 50% to 60% for customized products [20] Market Trends and Challenges - The domestic functional sugar market is experiencing slow growth due to consumer acceptance and regulatory approval delays [30] - The company is focusing on international markets for growth, particularly in the U.S., EU, and Japan, where there is significant potential for allulose and resistant dextrin [29][30] Future Outlook - The company maintains an optimistic outlook for Q2 2025 and the full year, expecting to meet performance targets set by the chairman [32] - Investors should pay attention to the approval status of allulose and other products, as national policies support the development of natural health foods and beverages [32]

Core Viewpoint - The major shareholder of Baolingbao, Ningbo Baopu Futong Asset Management Center, plans to reduce its stake by up to 3% through block trading and centralized bidding from June 24 to September 23, 2023, despite the company's recent performance recovery [2][7]. Shareholder Reduction - Baolingbao announced that Baopu Futong will reduce its holdings by no more than 3% of the total shares, with a maximum of 2% (7.3953 million shares) through block trading and 1% (3.6977 million shares) through centralized bidding [2][7]. - Since 2020, Baolingbao has disclosed seven announcements regarding Baopu Futong's share reductions, with six plans not executed. The only successful reduction was in July 2020, where 3.85% was reduced from a planned 5.4% [2]. Financial Performance - In 2024, Baolingbao's revenue was approximately 2.402 billion yuan, a decrease of 4.84% year-on-year, primarily due to adjustments in product structure and marketing strategies [4]. - The core business segments, including prebiotics, dietary fiber, and sugar-reducing sweeteners, showed significant recovery, with revenues of approximately 335 million yuan (up 16.02%), 238 million yuan (up 14.52%), and 516 million yuan (up 29.73%) respectively [4]. - In Q1 2025, Baolingbao achieved a revenue of approximately 685 million yuan, a year-on-year increase of 24.23%, and a net profit attributable to shareholders of approximately 50.36 million yuan, up 117.35% [6][7]. Market Dynamics - The European market for Baolingbao's erythritol products has seen an increase in both volume and price following the EU's anti-dumping investigation [5]. - The company is focusing on high-end products such as prebiotics, dietary fiber, and sugar-reducing sweeteners, adopting a business model that emphasizes small-batch, high-value, and differentiated orders [8]. Management Changes - Baolingbao has experienced frequent changes in its executive team, with several high-level resignations in early 2023. Analysts suggest that while some departures may be due to personal reasons, others could relate to operational adjustments [9]. - The competitive landscape for sugar-reducing sweeteners includes major players like Jinhe Industrial and Sanyuan Biological, which have advantages in product development and market channels [9][10]. R&D and Future Outlook - Baolingbao is increasing its investment in allulose, with a technical transformation project set to produce over 5,000 tons annually, and a second-phase expansion project planned for 20,000 tons [10]. - Despite the growth in the sugar-reducing sweetener market, industry analysts express caution regarding the pace of product innovation and the competitive gap between Baolingbao and leading companies [10].